Q-omics provides the consensus-scored FBXO34 profile across patient tissues and cancer cell-line models. FBXO34 expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, FBXO34 is differentially expressed in 9, with the highest sampling consensus in KIRC. Additionally, FBXO34 RNA expression shows 20,396 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KIRC, and ACC as cancer lineages where FBXO34 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FBXO34 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FBXO34 survival associations across molecular data types. FBXO34 RNA expression shows survival associations in the most cancer types (19), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FBXO34 RNA expression–survival associations across cancer types. High FBXO34 expression shows unfavorable associations in ACC, MESO and SARC, but favorable associations in KIRC, BRCA and SCLC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for FBXO34 RNA expression.
This table summarizes FBXO34 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for FBXO34. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FBXO34 shows lower tumor expression in KIRC, THCA and COAD and higher tumor expression in BLCA, CHOL and KIRP. The KIRC box plot shows higher FBXO34 RNA expression in normal versus tumor tissue (log2 FC = −0.687, t-test p < 0.001).
This table shows molecular features associated with FBXO34 in patient tissues and cancer cell lines. In patient samples, FBXO34 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, FBXO34 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and BLOOD_Leukemia.
